Based on 15 years of research into the relationship between the autonomic nervous system, psychological state and circadian heart rhythm (CHR) architecture, Medibio’s patented technology has the potential to be the world’s first objective test for mental health.

Medibio’s Digital Mental Health Platform will transform the assessment and management of mental health by:

  • Providing objective, quantifiable diagnosis
  • Confirming the effectiveness of therapies
  • Driving optimal disease management

Depression is estimated to cost US economy US$210 billion a year with the cost in Australia estimated at $12.6 billion annually.

MEB’s Mental Health Diagnostic Test

  • Medibio has developed the potential to be the world’s first FDA approved diagnostic test for mental illness for depression.
  • This patented innovative unique technology is non-intrusive, quick, objective, decisive and will revolutionise the diagnosis and treatment of mental health.
  • Over 15 years of research into the relationship between the autonomic nervous system, psychological state and heart rate activity.
  • Depression is estimated to cost US economy US$210 billion a year with the cost in Australia estimated at $12.6 billion annually.
  • Currently rolling out our Corporate Stress Product with Wellness Channel partners.

“We will no longer endorse DSM5, as it has fundamental flaws and we are actively seeking a diagnostic system that is evidence based. We need a quantitative method for diagnosing depression. It is critical to realize that we cannot succeed if we use DSM categories as the gold standard.”

U.S. National Institute of Mental Health May 2013